SLC16A1 and cancer: To explore indoles as potential novel molecular–structuralclass of MCT1 inhibitors, we extended the structural diversity ofindoles by synthesizing 16 derivatives including their comprehensive in vitro assessment against MCT1-mediated transport, cancercell viability, and cancer cell cycle, but also against selected drugtransporters.